Physician, Patient Events Showcase ReShape™ Integrated Dual Balloon System at ObesityWeek 2015

ReShape Medical, Inc.'s First Medical Conference since FDA Approval Paves the Way for 2016

Nov 09, 2015, 09:31 ET from ReShape Medical, Inc.

LOS ANGELES & SAN CLEMENTE, Calif., Nov. 9, 2015 /PRNewswire/ -- ReShape Medical® today spotlighted key physician and patients events that took place during ObesityWeek 2015, the annual meeting of both the American Society for Metabolic & Bariatric Surgery (ASMBS) and The Obesity Society (TOS), last week in Los Angeles. In its first key medical conference since FDA approval of the ReShape™ Integrated Dual Balloon System, ReShape Medical focused on physician training and education, as well as its commitment to comprehensive patient care.   

"First generation intragastric balloons have been shown to be safe and effective outside the U.S. for many years," said Rick Thompson, President and CEO of ReShape Medical, Inc. "We were very pleased with the physician reception during the conference to the advanced features of our next generation dual balloon and comprehensive patient care program that was recently FDA approved and launched in this country. The many clinical and educational programs we hosted and participated in last week will help more physicians successfully integrate ReShape into their practice, and increase patient awareness of ReShape going into 2016."

During the conference, ReShape Medical focused on educating physicians on the dual balloon system as an option for patients in the 30-40 BMI range who don't qualify for or don't want bariatric surgery, and how ReShape may integrate into a bariatric practice to serve a new patient population. ReShape hosted and participated in several training programs, including three CME courses, and a private physician symposium which was attended by more than 100 current and prospective ReShape users. Jaime Ponce, MD, of Chattanooga Bariatrics and lead investigator from the REDUCE pivotal trial, presented during the Emerging Technologies Paper Session.

"For bariatric surgeons, the ReShape Procedure represents a completely new option to offer patients in the 30-40 BMI range who we historically would not have been able to treat," said Dr. Thomas Lavin, who was among the first bariatric surgeons in the country to offer ReShape. "Implementing ReShape into clinical practice goes beyond the procedure itself - it requires understanding these patients' long-term needs and ensuring our practices have the tools and training in place to help them achieve a lasting healthy lifestyle. In the first two months our patients have been extremely happy with the procedure's safety, convenience, and ease of weight loss."

ReShape also participated in a patient-focused event, Your Weight Matters Local Events (YWMLocal LA 2015) hosted by the Obesity Action Coalition and presented in conjunction with ObesityWeek 2015. The free event welcomed Los Angeles-area residents newly starting or re-engaging in their journey to improved weight to learn more about nutrition, exercise, weight-loss treatment options and more.

"Individuals with obesity often struggle for years, and the availability of ReShape provides patients with another tool to address their weight and health," said Joe Nadglowski, President and CEO of the OAC. "Educating patients about new evidence-based treatments is a critical step toward improving the health of those with obesity."

About the ReShape Integrated Dual Balloon System
The ReShape Dual Balloon is a next generation technology designed to enhance performance in three important areas.  First, two connected balloons have the largest fill volume available, taking up more space in the stomach than the old style single balloons.  Second, it is designed for greater comfort by distributing the fill volume across two balloons, connected by a flexible shaft, which allows the device to conform to the natural shape of the stomach.  Finally, the ReShape Integrated Dual Balloon is the only intragastric balloon that is designed to help prevent the migration of a deflated balloon from the stomach into the intestines.

In a U.S. randomized, sham control, double blinded study, patients that had the ReShape Procedure lost 2.3 times as much weight as a control group that received diet and exercise coaching only. There were also measurable and sustained improvements in co-morbidities and strong patient satisfaction.  In a study of the ReShape Procedure in commercial use in Europe, ReShape patients on average lost 36 pounds, or 47% of their excess weight at six months and maintained 94% of their weight loss at one year.

About ReShape Medical, Inc.
ReShape Medical, Inc. is a medical device company focused on the development and commercialization of its dual intragastric balloon for weight loss. Driven by a passion to address the worldwide obesity epidemic, the company has developed a non-surgical alternative for obese patients seeking treatment. Additional company information can be found at The ReShape Procedure has been available in the European Union since December 2011.

Media Contact:
Wendy Ryan/Rachel Gross 

RESHAPE and the RESHAPE MEDICAL Logo are trademarks of ReShape Medical, Inc.


SOURCE ReShape Medical, Inc.